{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:58:27Z","timestamp":1774015107834,"version":"3.50.1"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gdansk Medical University","award":["ST 02-100-25"],"award-info":[{"award-number":["ST 02-100-25"]}]},{"name":"Gdansk Medical University","award":["01-100-26"],"award-info":[{"award-number":["01-100-26"]}]},{"name":"Gdansk Medical University","award":["01-50025\/0008399\/01\/524\/524\/0\/2025"],"award-info":[{"award-number":["01-50025\/0008399\/01\/524\/524\/0\/2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Kidney transplantation (KTx) corrects many uremia-related metabolic disturbances; however, dyslipidemia remains common in kidney transplant recipients and contributes to persistent cardiovascular risk. Lipoprotein(a) [Lp(a)] is a largely genetically determined proatherogenic lipoprotein that increases in advanced chronic kidney disease (CKD) and may decrease after restoration of renal function. Autotaxin (ATX), an enzyme involved in proinflammatory lipid signaling through the ATX\u2013lysophosphatidic acid axis, has also been implicated in cardiovascular pathology, but its early post-transplant dynamics remain poorly characterized. In addition to quantitative lipid abnormalities, CKD is associated with high-density lipoprotein (HDL) dysfunction and reduced paraoxonase-1 (PON-1) activity; however, data on early post-transplant changes in PON-1 activity are limited. In this prospective observational study, lipid profile parameters, Lp(a) concentration, ATX activity, and PON-1 activity were assessed in 55 Caucasian patients with CKD stage 5, most of whom were dialysis-dependent, before and 2\u20133 weeks after KTx. All recipients received tacrolimus-based maintenance immunosuppression with corticosteroids and mycophenolate mofetil. After KTx, Lp(a) levels decreased by a median of 21% and ATX activity by 28% (both p &lt; 0.001). Lp(a) and ATX showed no cross-sectional or longitudinal association either before or after transplantation, and their percentage changes were not correlated. In contrast, conventional lipid fractions increased significantly, including total cholesterol (+22%), LDL cholesterol (+27%), HDL cholesterol (+24%), and triglycerides (+55%) (all p &lt; 0.001). PON-1 activity increased by approximately 13% after KTx (p &lt; 0.001), and its percentage change correlated positively with the increase in HDL cholesterol. In exploratory analyses, the magnitude of Lp(a) reduction was associated with early graft function: patients with eGFR &lt;45 mL\/min\/1.73 m2 exhibited a significantly smaller decline in Lp(a) than those with better graft function (\u22124.8% vs. \u221226.7%, p = 0.009). Multivariable analysis showed that demographic characteristics, body mass index, tacrolimus exposure, and post-transplant eGFR did not independently predict the magnitude of Lp(a) reduction. Tacrolimus trough concentrations and cumulative corticosteroid exposure were not associated with lipid parameters or their changes, except for a single subgroup difference in PON-1 activity of uncertain clinical significance. In summary, in the early period after KTx under tacrolimus-based immunosuppression, Lp(a) concentration and ATX activity decrease, whereas conventional lipid fractions increase and PON-1 activity improves. These changes were not associated with tacrolimus exposure or cumulative corticosteroid dose. The reduction in Lp(a) was associated with early graft function in exploratory analyses, suggesting that recovery of renal function may contribute to early post-transplant Lp(a) dynamics; however, no independent causal relationship was established, and the findings should be interpreted cautiously given the limited sample size and exploratory design. The clinical significance of these changes for long-term cardiovascular and graft outcomes requires further investigation.<\/jats:p>","DOI":"10.3390\/ijms27062641","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:59:44Z","timestamp":1773406784000},"page":"2641","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Post-Transplant Changes in Lipoprotein(a), Autotaxin Activity, and Lipid Profile: A Prospective Observational Study of Tacrolimus-Treated Kidney Transplant Recipients in Poland"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-4072","authenticated-orcid":false,"given":"Beata","family":"Bzoma","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, University Clinical Center in Gda\u0144sk, Smoluchowskiego 17, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-1442","authenticated-orcid":false,"given":"Agnieszka","family":"Kuchta","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Clinical Center in Gda\u0144sk, Medical University of Gda\u0144sk, D\u0119binki 7, 80-210 Gda\u0144sk, Poland"},{"name":"Central Clinical Laboratory, University Clinical Center in Gda\u0144sk, D\u0119binki 7, 80-952 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Dzwonkowska","sequence":"additional","affiliation":[{"name":"Central Clinical Laboratory, University Clinical Center in Gda\u0144sk, D\u0119binki 7, 80-952 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Kazimierska","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Clinical Center in Gda\u0144sk, Medical University of Gda\u0144sk, D\u0119binki 7, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4540-6955","authenticated-orcid":false,"given":"Maciej","family":"Jankowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Clinical Center in Gda\u0144sk, Medical University of Gda\u0144sk, D\u0119binki 7, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-8063","authenticated-orcid":false,"given":"Alicja","family":"D\u0119bska-\u015alizie\u0144","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, University Clinical Center in Gda\u0144sk, Smoluchowskiego 17, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","article-title":"Lipoproteins in chronic kidney disease: From bench to bedside","volume":"42","author":"Speer","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-025-01290-2","article-title":"Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk","volume":"27","author":"Theofilis","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: Results from the German Chronic Kidney Disease study","volume":"296","author":"Gruber","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1172\/JCI116221","article-title":"Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production","volume":"91","author":"Rader","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"Rader","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein(a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1681\/ASN.V351156","article-title":"Increased lipoprotein(a) concentrations in chronic renal failure","volume":"3","author":"Haffner","year":"1992","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in renal disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/0886022X.2010.486097","article-title":"Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease","volume":"32","author":"Aggarwal","year":"2010","journal-title":"Ren. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"ref_13","first-page":"364","article-title":"Effect of renal transplantation on lipoprotein(a) concentration","volume":"14","author":"Yang","year":"1994","journal-title":"Am. J. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0021-9150(99)00014-3","article-title":"Lipoprotein(a) plasma concentrations after renal transplantation: A prospective evaluation after 4 years of follow-up","volume":"144","author":"Kerschdorfer","year":"1999","journal-title":"Atherosclerosis"},{"key":"ref_15","first-page":"481","article-title":"Lipoprotein(a) levels in renal transplant patients: Relationship with renal function and lipoprotein profile","volume":"59","author":"Cassader","year":"1991","journal-title":"Nephron"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000189549","article-title":"Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation","volume":"75","author":"Brown","year":"1997","journal-title":"Nephron"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/clinchem\/38.3.353","article-title":"Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism","volume":"38","author":"Black","year":"1992","journal-title":"Clin. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2362.1996.tb02151.x","article-title":"Decrease in Lipoprotein(a) After Renal Transplantation Is Related to the Glucocorticoid Dose","volume":"26","author":"Helmhold","year":"1996","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","article-title":"Lipoprotein(a) and calcific aortic valve disease initiation and progression: A systematic review and meta-analysis","volume":"119","author":"Pantelidis","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lampsas, S., Xenou, M., Oikonomou, E., Pantelidis, P., Lysandrou, A., Sarantos, S., Goliopoulou, A., Kalogeras, K., Tsigkou, V., and Kalpis, A. (2023). Lipoprotein(a) in atherosclerotic diseases: From pathophysiology to diagnosis and treatment. Molecules, 28.","DOI":"10.3390\/molecules28030969"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am. J. Transpl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of cardiovascular disease in adult recipients of kidney transplants","volume":"378","author":"Jardine","year":"2011","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings from the CRIC Study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s40620-023-01590-3","article-title":"Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: A systematic review of prospective studies","volume":"36","author":"Barbagelata","year":"2023","journal-title":"J. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCA.0000000000000692","article-title":"Association of lipoprotein(a) and coronary artery disease in 1003 patients with stage 3\u20135 chronic kidney disease undergoing coronary angiography","volume":"30","author":"Lin","year":"2019","journal-title":"Coron. Artery Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clinbiochem.2006.10.009","article-title":"Measurement of Lysophospholipase D\/Autotaxin Activity in Human Serum Samples","volume":"40","author":"Nakamura","year":"2007","journal-title":"Clin. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7555\/JBR.30.20150058","article-title":"Recent advances in targeting the auto-taxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo","volume":"30","author":"Benesch","year":"2016","journal-title":"J. Biomed. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.transproceed.2014.12.029","article-title":"Risk factors and incidence for lipid abnormalities in kidney transplant patients","volume":"47","author":"Ichimaru","year":"2015","journal-title":"Transplant. Proc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/ndt\/gfaf104","article-title":"Lipid-lowering agents in solid organ transplant recipients","volume":"40","author":"Mickiewicz","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMra2014530","article-title":"Long-term survival after kidney transplantation","volume":"385","author":"Hariharan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11892-009-0047-0","article-title":"Dyslipidemia following kidney transplantation: Diagnosis and treatment","volume":"9","author":"Badiou","year":"2009","journal-title":"Curr. Diabetes Rep."},{"key":"ref_32","first-page":"565\u2013585; quiz 586\u2013587","article-title":"Drug-related dyslipidemia after renal transplantation","volume":"61","author":"Mathis","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MNH.0000000000000841","article-title":"Lipid management to mitigate poorer postkidney transplant outcomes","volume":"32","author":"Skulratanasak","year":"2023","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.transproceed.2011.08.074","article-title":"Lipid profile changes during the first year after kidney transplantation: Risk factors and influence of the immunosuppressive drug regimen","volume":"43","author":"Spinelli","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)92616-2","article-title":"Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?","volume":"341","author":"Webb","year":"1993","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1432-2277.2001.tb00079.x","article-title":"Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients","volume":"14","author":"Venkiteswaran","year":"2001","journal-title":"Transpl. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2165\/00003495-200464180-00004","article-title":"Effect of immunosuppressive agents on long-term survival of renal transplant recipients: Focus on the cardiovascular risk","volume":"64","author":"Boots","year":"2004","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/01.ASN.0000071515.27754.67","article-title":"Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus","volume":"14","author":"Artz","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3760\/cma.j.issn.0366-6999.20140518","article-title":"Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: A meta-analysis","volume":"127","author":"Xue","year":"2014","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.V122368","article-title":"Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus","volume":"12","author":"Ligtenberg","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1016\/j.transproceed.2009.09.069","article-title":"Effects of cyclosporine\u2013tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2\/3, lipoprotein A1\/B, and other lipid parameters","volume":"41","author":"Seymen","year":"2009","journal-title":"Transplant. Proc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1053-2498(98)00060-6","article-title":"A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus","volume":"18","author":"Taylor","year":"1999","journal-title":"J. Heart Lung Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrneph.2015.180","article-title":"HDL abnormalities in nephrotic syndrome and chronic kidney disease","volume":"12","author":"Vaziri","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rysz, J., Gluba-Brz\u00f3zka, A., Rysz-G\u00f3rzy\u0144ska, M., and Franczyk, B. (2020). The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020601"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cca.2012.10.003","article-title":"Decrease in circulating autotaxin by oral administration of prednisolone","volume":"415","author":"Sumida","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"JACC"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.V1251052","article-title":"Impact of apolipoprotein(a) phenotypes on long-term renal transplant survival","volume":"12","author":"Wahn","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5551\/jat.10.337","article-title":"The ratio of serum paraoxonase\/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192)","volume":"10","author":"Nakanishi","year":"2003","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_53","unstructured":"Durlik, M., and Kosieradzki, M. (2024). Recommendations on Immunosuppressive Treatment After Vascularized Organ Transplantation, Polish Transplantation Society."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:45:00Z","timestamp":1774007100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062641"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062641","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}